| Assessment Status | Rapid Review complete |
| HTA ID | 21010 |
| Drug | Brentuximab vedotin |
| Brand | Adcetris® |
| Indication | In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). |
| Assessment Process | |
| Rapid review commissioned | 24/03/2021 |
| Rapid review completed | 23/04/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin (Adcetris®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations, December 2022.
